Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02276222 · ClinicalTrials.gov registry record · Phase 3
A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD
A Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by Sunovion Respiratory Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,087
- Enrollment target
- 20
- Study locations
NCT02276222: Completed Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by Sunovion Respiratory Development.
NCT02276222 is a Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD) that has completed, run by Sunovion Respiratory Development. The registered enrollment target is 1,087 participants, above the 621-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (75% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02276222, a Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), has completed, sponsored by Sunovion Respiratory Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,087 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a long-term safety trial of 48 weeks. Eligible subjects will enter the 48-week, open-label treatment period to receive one of two treatments (SUN-101 given as 50 mcg twice a day or Spiriva® \[tiotropium\] given as 18 mcg once a day).
Primary Outcome
A TEAE is any adverse event (AE) that occurred on or after the first dose of study medication, any AE with a missing start date and a stop date on or after the first dose of study medication, or any AE with both a missing start and stop date.
Conditions Studied
Interventions
- DRUG SUN-101 50 mcg BID eFlow (CS) nebulizer
- DRUG Spiriva® 18 mcg QD Handihaler
Study Locations (20)
Florida
- Tampa Bay Clinical Research Center - Brandon
- Clinical Research of West Florida - Clearwater
- Avail Clinical Research, llC - DeLand
- The Community Research of South Florida - Hialeah
- AppleMed Research, Inc - Miami
- Research Institute of South Florida, Inc - Miami
- Clinical Trials of Florida, LLC - Miami
- Florida Institute For Clinical Research, LLC - Orlando
California
- Allianz Research Institute, Inc. - Fountain Valley
- Research Center of Fresno, Inc. - Fresno
- California Research Medical Group, lnc. - Fullerton
- Southern California Institute For Respiratory Diseases, Inc. - Los Angeles
- Integrated Research Group, Inc - Riverside
- Institute of Healthcare Assessments Inc. - San Diego
Alabama
- SEC Lung LLC - Andalusia
- Achieve Clinical Research LLC - Birmingham
- Jasper Summit Research LLC - Jasper
Arizona
- Clinical Research Advantage, Inc.lEast Valley Family Physicians, PLC - Chandler
- Desert Sun Clinical Research LLC - Tucson
Connecticut
- Waterbury Pulmonary Associates, LLC - Waterbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,087 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-02 |
| Phase | Phase 3 |
What the finished NCT02276222 record still lists
NCT02276222 is an interventional study that assigns participants to a tested intervention. Its 1,087 participants enrollment target places it among the larger protocols in the corpus, above the 621-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (75% higher).
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease (COPD) appearing as the primary indexed condition, and to 2 interventions - of which SUN-101 50 mcg BID eFlow (CS) nebulizer is the first listed.
NCT02276222 names 20 study sites across 5 states, led by Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT02276222 about?
NCT02276222 is a clinical study titled "A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD". This is a long-term safety trial of 48 weeks. Eligible subjects will enter the 48-week, open-label treatment period to receive one of two treatments (SUN-101 given as 50 mcg twice a day or Spiriva® \[tiotropium\] given as 18 mcg once a day).
What is the current status of trial NCT02276222?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,087 participants. The study started on 2014-10. Estimated completion is 2016-02.
What conditions does trial NCT02276222 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease (COPD).
What interventions are being tested in trial NCT02276222?
The interventions under investigation include: SUN-101 50 mcg BID eFlow (CS) nebulizer (DRUG), Spiriva® 18 mcg QD Handihaler (DRUG).
Who is sponsoring clinical trial NCT02276222?
This trial is sponsored by Sunovion Respiratory Development, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02276222 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease (COPD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02276222's enrollment target sits among peer trials
1,087 10th of 36 higher than 27 of 36 other Chronic Obstructive Pulmonary Disease (COPD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Obstructive Pulmonary Disease (COPD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Multi-Center Clean Air Randomized Controlled Trial in COPD
RECRUITING · Phase 3
-
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
RECRUITING · Phase 3
-
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06671483 · 1,088 participants · Phase 3
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
- NCT07196722 · 1,092 participants · Phase 2
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- NCT03754114 · 1,094 participants · NA
Brain Oxygen Optimization in Severe TBI, Phase 3
- NCT06118983 · 1,094 participants · NA
Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia